Novo Nordisk inked an obesity deal worth up to $2.2 billion on Wednesday, and sent shares of Septerna into the stratosphere.

CVS Health CVS shares have rallied nearly 38% so far this month, driven by the company’s stronger-than-expected first-quarter ...

Novo Nordisk is doubling down on its oral drug strategy for obesity with a new partnership worth up to $2.2bn with Septerna.

Novo Nordisk (NVO) announced a new $2.2 billion deal with San Francisco-based biotech Sapterna (SEPN) for obesity pills.

Novo Nordisk (NVO) announced a new $2.2 billion deal with San Francisco-based biotech Sapterna (SEPN) for obesity pills.

Despite its expensive valuation and declining estimates, we suggest investors hold LLY stock as the company boasts solid ...